ZP1846

  • 2010

    8. juni 2010:Pressemeddelelse nr. 5, 2010: Zealand Pharma Announces An Extension of The Lixisenatide...

    Read More >

  • Meet us

    The 31st European Peptide Symposium, Copenhagen, Denmark, 5-9 September 2010 (Science) 46th An...

    Read More >

ZP1846

Glucagon-like Peptide-2 (GLP-2) is a peptide growth factor that specifically targets and stimulates growth of the intestinal epithelium. In experimental models of small intestinal injury and disease, administration of GLP-2 remarkably enhanced the repair, regeneration and absorptive capacity of the small intestinal mucosa. These findings aroused significant interest for the potential therapeutic use of GLP-2 in the treatment of intestinal disease and injury although the known relative instability of the peptide in the body represented a significant challenge.

ZP1846 is a SIP® modified novel GLP-2 peptide analogue with enhanced stability and efficacy. In pre-clinical pharmacological studies, ZP1846 consistently stimulates growth of the small intestinal mucosa and decreases the incidence and severity of Chemotherapy-Induced Diarrhea (CID).

It is anticipated that use of ZP1846 may ameliorate or prevent the destructive effects of chemotherapy on the small intestine and thereby reduce the incidence of diarrhea.  Based on the Company’s pre-clinical data a Phase I clinical evaluation in healthy volunteers was finalized mid 2008 in the U.S.

ZP1846 was outlicensed to Helsinn Healthcare SA in November 2008.

Helsinn has initiated a Phase I – safety and tolerability study in colorectal patients in 2010.

 

To top of page

Tip a friend

Fill in the form below to tip a friend about this page.






Subscribe

When this page is updated you will be updated by e-mail.